Clinical Trials
5
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Pharmacokinetics Study on Healthy Volunteers Adults
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Antabio
- Target Recruit Count
- 25
- Registration Number
- NCT06916156
- Locations
- 🇺🇸
Pulmonary Associates, PA, Phoenix, Arizona, United States
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Antabio
- Target Recruit Count
- 41
- Registration Number
- NCT06527677
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Antabio
- Target Recruit Count
- 72
- Registration Number
- NCT05905913
- Locations
- 🇫🇷
Biotrial, Rennes, France
News
Antabio's MEM-ANT3310 Completes Phase 1 Trial, Showing Promise Against Multidrug-Resistant Infections
Antabio's MEM-ANT3310, a novel antibacterial combination, has successfully completed its Phase 1 clinical trial in healthy volunteers, demonstrating good tolerability.